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ABSTRACT
Objectives: Hospital administrative data were analyzed
to assess treatment patterns, in-hospital mortality, rates of
hemorrhagic events and thrombus propagation, utiliza-
tion of health care resources, and hospital costs associated
with various treatments during inpatient care for venous
thromboembolism (VTE).
Study Design: Data from inpatient records were collected
for deep venous thrombosis (DVT) and pulmonary embo-
lism (PE) encounters at 132 US hospitals between January
1999 and December 2000. Patients receiving the most fre-
quently employed treatments were compared with respect
to demographics, related procedures and diagnostics,
length of stay, adverse events, in-hospital mortality, and
hospital costs.
Results: A total of 953 primary DVT and 3933 primary
PE admissions were identiﬁed. Most admissions involved
treatment with unfractionated heparin and vitamin K
antagonist (UFH/VKA, 64.2% of admissions), followed
by  UFH  with  VKA  and  low-molecular-weight  he-
parin (UFH/LMWH/VKA, 14.4%), and LMWH/VKA
(12.9%). Compared with those treated with UFH/VKA,
patients treated with LMWH/VKA experienced higher
anticoagulant costs ($540 vs. $106), but lower total hos-
pital costs ($5198 vs. $5977) and shorter lengths of stay
(4.4 vs. 5.7 days for those without PE and 5.7 vs. 6.7 days
for those with PE).
Conclusions: UFH/VKA was the most common regimen
used to treat VTE. In spite of its higher medication cost,
however, treatment with LMWH/VKA was associated
with signiﬁcantly shorter hospital stays and lower total
hospitalization costs, compared with UFH/VKA.
Keywords: anticoagulants, economics, health services/
utilization, heparin, hospitalization, length of stay, out-
come assessment (health care), physician’s practice pat-
terns, pulmonary embolism, venous thrombosis.
Introduction
Venous thromboembolism (VTE) is responsible for
approximately 300,000 to 600,000 hospitalizations
in the United States each year [1,2], and for thou-
sands of preventable deaths among hospitalized
patients [1–3]. Patients admitted with VTE may
receive initial treatment with either intravenous
unfractionated heparin (UFH) or low-molecular-
weight heparin (LMWH) [4–6]. Speciﬁc tests and
procedures used for monitoring VTE patients
undergoing therapy will differ based on the treat-
ment regimen employed. Whereas patients treated
with LMWH require no laboratory monitoring,
patients receiving UFH require serial activated par-
tial thromboplastin time (aPTT) determinations
[5,7,8]. Treatment with vitamin K antagonist (VKA;
i.e., warfarin) requires frequent monitoring of pro-
thrombin time (PT; International Normalized Ratio
[INR]) [5,7,8]. Ordering of other tests and proce-
dures (e.g., serial venous ultrasound examinations
of lower extremities, chest x-rays, ventilation-
perfusion [VQ] scans) may be inﬂuenced by physi-
cian perception of the safety and efﬁcacy of the
treatment strategy chosen. Potential adverse out-
comes for individuals with VTE during their
hospital course include hemorrhagic events, throm-
boembolic events, thrombus propagation, and
death [1].
There are limited data documenting common
strategies used for inpatient treatment of VTE, or
describing the hospital course of patients on each of
these regimens. Data are also lacking to describe
costs associated with common treatment modalities
for VTE. The objectives of this study are to describe
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hospital treatment patterns, in-hospital mortality,
occurrence of hemorrhagic events and thrombus
propagation, use of speciﬁc tests and procedures,
and medication and total hospital costs associated
with common treatment modalities. Such informa-
tion has potential implications for both medical
care providers and payers wishing to identify gaps
in the quality of care delivered to patients hosp-
italized with VTE and/or to identify cost-saving
opportunities.
Methods
Study Population
Hospital admissions for VTE between January 1,
1999 and December 31, 2000 were identiﬁed by
using Diagnostic Related Group (DRG) codes or All
Patient Reﬁned DRG (APR-DRG) codes. Admis-
sions satisfying any of the following criteria were
included: 1) DRG of 78 or 128; and 2) APR-DRG
of 134 or 195.
Given the lack of information on admitting diag-
nosis, only those admissions with anticoagulant
administered within the ﬁrst 48 hours of hospitali-
zation were included. Admissions involving patients
younger than age 18 years were eliminated. A single
patient could have contributed more than one
admission during the 2-year study period.
Study Design and Data Sources
The study utilized an observational cohort design
using a large administrative hospital database
(Premier Healthcare Informatics). The database
contains standard administrative information for
admissions at 132 US facilities occurring between
January 1, 1999 and December 31, 2000, including
the following:
1. Hospital characteristics;
2. Patient demographics;
3. Diagnostic and procedure codes;
4. Drugs administered.
Approval for the study was obtained from the
Institutional Review Board at Cedars-Sinai Health
System, Los Angeles, CA, USA, including chart
review and use of hospital administrative data.
Data Analysis
Treatment groups. Admissions were classiﬁed into
six treatment groups as follows:
1. UFH and VKA;
2. LMWH and VKA;
3. UFH, LMWH, and VKA;
4. UFH and LMWH;
5. LMWH monotherapy;
6. UFH monotherapy.
The ﬁrst three of these groups were of primary
interest and formed the basis of most of the
analyses.
Related procedures. Procedures and diagnostics
identiﬁed as potentially related to VTE included PT,
aPTT, complete blood count (CBC), chest X-ray,
pulmonary angiogram, venogram, computed tomo-
graphic (CT) scan, ultrasound, magnetic resonance
imaging (MRI), VQ scan, and plethysmography.
The frequencies of these procedures and diagnostics
were determined for patients in each of the treat-
ment groups.
Length of stay. Mean lengths of stay (LOS) were
calculated for each of the treatment groups.
Adverse events. Adverse events potentially related
to deep venous thrombosis (DVT) or its treatment
were deﬁned as follows: 1) hemorrhage; 2) thro-
mbus propagation; 3) 30-day readmission; and 4)
in-hospital mortality. Hemorrhage and thrombus
propagation were identiﬁed by using International
Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation (ICD-9 CM) diagnosis codes corre-
sponding to these events. Thrombus propagation
was deﬁned as an ICD-9 CM diagnosis code of
453.1. Hemorrhages were identiﬁed by ICD-9 CM
diagnostic codes as listed in Table 1. A 30-day
readmission was deﬁned as an admission meeting
the criteria for VTE occurring within 30 days of the
discharge date speciﬁed for a previous episode.
After 30-day readmissions were identiﬁed, they
were stratiﬁed into the following categories: 1) a
VTE-related readmission; 2) a hemorrhage-related
readmission; or 3) a readmission unrelated to VTE
or  hemorrhage.  Patient  discharge  status  was  used
to determine hospital mortality. Proportions of
patients in each treatment group experiencing
adverse events were calculated.
Costs. The costs provided in the data set represent
reported actual costs for care during hospitalization
for VTE or are estimates derived using the costs to
charges function from the Medicare Cost Report.
Mean anticoagulant and total medication costs
were calculated for each treatment group assessed.
Total hospital costs include costs for all procedures,
tests, and medications provided during the inpatient
stay. Mean costs were calculated for each treatment
group, and the results of selected groups were
compared.
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Statistical analyses. Statistical analyses were per-
formed by using the SAS statistical package (SAS
Version 8.2, SAS Institute, Cary, NC, 2001) among
the three primary treatment groups. In addition to
presenting descriptive statistics, differences in the
means of continuous variables, including costs and
LOS, were evaluated by using a generalized linear
model after log transformation, and differences in
proportions were evaluated by using chi-square
tests.
Validation study. In order to test the speciﬁcity of
the methodology for identifying VTE admissions,
hospital chart reviews were conducted at a hospital
not included in the primary analysis (Cedars-Sinai
Medical Center). Medical records were selected for
patients hospitalized between January 1, 1999 and
December 31, 2000 by using the same patient selec-
tion criteria (identifying DRG/APR-DRG and anti-
coagulation within 48 hours) that were used to
select admissions from the hospital administrative
database. We also examined the time required to
reach a therapeutic INR and its relationship to LOS
in this validation sample, because the data required
to do so were not available in the larger data set.
Results
Treatment Patterns
A total of 4886 primary VTE admissions from 132
institutions were identiﬁed in the data set. Of these,
953 were DVT admissions and 3933 were PE
admissions. The distributions by type of anticoagu-
lant treatment were similar for DVT and PE groups.
The treatment regimen employed most frequently
was UFH/VKA (66.5% and 63.7% for DVT and PE
admissions, respectively). Remaining groups
included: LMWH/VKA (15.6% and 12.3%), UFH/
LMWH/VKA (9.0% and 15.7%), UFH (4.6% and
Table 1 Bleeding and hemorrhage ICD-9 CM codes
ICD-9 diagnosis codes Deﬁnition
Peripheral venous event
415.1x Pulmonary embolism and infarction
451.1¥-451.9x Phlebitis and thrombophlebitis
453.x Other venous embolism and thrombosis
Intracranial hemorrhage
430.xx Subarachnoid hemorrhage
431.xx Intracerebral hemorrhage
432.xx Other and unspeciﬁed intracranial hemorrhage
Other bleeding events
E934.2 Drugs causing adverse events in therapeutic use: anticoagulants
Bleeding and hemorrhage sites
246.3 Thyroid
362.81 Retina
363.61–363.62 Choroid
379.23 Vitreous hemorrhage
386.8 Cochlea
388.69 Ear
448.9 Capillary
459 Hemorrhage—unspeciﬁed
523.8 Gums
528.9 Mouth
530.82 Esophageal
531.0, 531.2, 531.4, 531.6 Gastric ulcer with hemorrhage
533.0, 532.2, 541.4, 531.6 Duodenal ulcer with hemorrhage
533.0, 533.2, 533.4, 533.6 Peptic ulcer with hemorrhage
Bleeding and hemorrhage sites
534.0, 534.2, 534.4, 534.6 Gastrojejunal ulcer with hemorrhage
537.83 Angiodysplasia of  stomach and duodenum with hemorrhage
562.03 Diverticulitis of  small intestine with hemorrhage
562.13 Diverticulitis of  large intestine with hemorrhage
568.81 Hemoperitoneum (nontraumatic)
569.3 Anal, rectal
569.83 Angiodysplasia of  intestine with hemorrhage
578.xx Gastrointestinal
596.8 Bladder
626.6 Uterine, unrelated to menstrual cycle
719.1x Joint (hemarthrosis)
727.89 Bursa
784.7 Nose
784.8 Throat
786.3 Cough with hemorrhage
958.2 Recurring, after injury
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6.3%), LMWH (2.4% and 1.1%), and UFH/
LMWH (1.8% and 0.9%).
Patient and Hospital Characteristics
The demographics of DVT and PE populations are
shown in Table 2 for the three most widely used reg-
imens. Overall, white women made up the largest
demographic subgroup. The mean age was similar
across treatments, and also between the DVT and
PE groups. As expected, PE admissions were of
greater severity (i.e., signiﬁcantly more were classi-
ﬁed as types III or IV on the APR-DRG Severity
Index) compared with DVT admissions.
Table 2 also provides a summary of hospital char-
acteristics. Facilities were disproportionately located
in southern US states. DVT admissions occurred dis-
proportionately at midsized hospitals, those ranging
from 100 to 499 beds, whereas PE admissions
occurred to a greater extent at large facilities, those
ranging from 300 to 500 or more beds.
Related Procedures
Table 3 lists the number of VTE-related procedures
by treatment regimen for DVT and PE admissions.
Treatment with UFH/LMWH/VKA was associated
with greater use of related procedures, while
LMWH/VKA-treated patients with DVT alone and
UFH/VKA-treated patients with PE received fewer
services.
Length of  Stay
Mean  LOS  for  each  type  of  treatment  are  shown
in Figure 1 for DVT admissions, and Figure 2 for
PE admissions. Mean LOS differed signiﬁcantly
(P < 0.0001) across treatment groups (Table 3 and
Fig. 2). Mean LOS was shortest for both DVT and
Table 2 Admissions for VTE—demographics and hospital characteristics by admission type and treatment group
DVT PE
UFH/VKA
(n = 634)
LMWH/
VKA
(n = 149)
UFH/LMWH/
VKA
(n = 86)
UFH/VKA
(n = 2504)
LMWH/VKA
(n = 484)
UFH/LMWH/VKA
(n = 617)
Age, mean 
years (SD)
64.2 (17.4) 64.1 (16.5) 61.3 (17.1) 62.7 (17) 63.5 (17.2) 62.3 (17.9)
Sex, n (%)
Female 355 (56) 90 (60.4) 58 (67.4) 1495 (59.7) 295 (61) 384 (62.2)
Male 279 (44) 59 (39.6) 28 (32.6) 1009 (40.3) 189 (39.1) 233 (37.8)
Race, n (%)
American 
Indian
5 (0.8) 1 (0.7) 0 (0) 7 (0.3) 2 (0.4) 1 (0.2)
Asian/Paciﬁc
Islander
1 (0.2) 1 (0.7) 0 (0) 2 (0.1) 1 (0.2) 1 (0.2)
Black 76 (12) 6 (4) 10 (11.6) 318 (12.7) 56 (11.6) 77 (12.5)
Hispanic 3 (0.5) 1 (0.7) 1 (1.2) 46 (1.8) 8 (1.7) 20 (3.2)
Other 91 (14.4) 7 (4.7) 7 (8.1) 354 (14.1) 66 (13.6) 74 (12)
White 458 (72.2) 133 (89.3) 68 (79.1) 1777 (71) 351 (72.5) 444 (72)
APR-DRG 
Severity, n (%)
Severity 0 1 (0.2) 0 (0) 0 (0) 6 (0.2) 5 (1) 0 (0)
Severity I 242 (38.2) 55 (36.9) 24 (27.9) 427 (17.1) 69 (14.3) 98 (15.9)
Severity II 295 (46.5) 68 (45.6) 46 (53.5) 1360 (54.3) 253 (52.3) 280 (45.4)
Severity III 91 (14.4) 26 (17.5) 15 (17.4) 630 (25.2) 144 (29.8) 200 (32.4)
Severity IV 5 (0.8) 0 (0) 1 (1.2) 81 (3.2) 13 (2.7) 39 (6.3)
Hospital type,
n (%)
Government 71 (11.2) 13 (8.7) 6 (7) 184 (7.4) 36 (7.4) 32 (5.2)
Nonproﬁt 563 (88.8) 136 (91.3) 80 (93) 2314 (92.4) 448 (92.6) 582 (94.3)
Proﬁt 0 (0) 0 (0) 0 (0) 6 (0.2) 0 (0) 3 (0.5)
Region, n (%)
Midwest 43 (6.8) 10 (6.7) 6 (7) 177 (7.1) 27 (5.6) 43 (7)
North 17 (2.7) 4 (2.7) 6 (7) 215 (8.6) 6 (1.2) 47 (7.6)
South 529 (83.4) 108 (72.5) 57 (66.3) 1854 (74) 372 (76.9) 458 (74.2)
West 45 (7.1) 27 (18.1) 17 (19.8) 258 (10.3) 79 (16.3) 69 (11.2)
Number of  beds,
n (%)
Below 100 36 (5.7) 8 (5.4) 4 (4.7) 102 (4.1) 28 (5.8) 24 (3.9)
100–199 143 (22.6) 34 (22.8) 16 (18.6) 422 (16.9) 95 (19.6) 96 (15.6)
200–299 122 (19.2) 18 (12.1) 12 (14) 416 (16.6) 56 (11.6) 82 (13.3)
300–499 215 (33.9) 53 (35.6) 34 (39.5) 837 (33.4) 142 (29.3) 157 (25.5)
500+ 118 (18.6) 36 (24.2) 20 (23.3) 727 (29) 163 (33.7) 258 (41.8)
APR-DRG, all patient reﬁned diagnostic-related group; DVT, deep venous thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; UFH, unfrac-
tionated heparin; VKA, vitamin K antagonist.
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PE groups, in the LMWH/VKA group, followed by
the UFH/VKA and UFH/LMWH/VKA groups.
Adverse Events
The  frequencies  of  VTE-related  adverse  events
are provided in Table 4 for DVT and PE admissions.
Thrombus propagation was infrequent; it only
occurred in three episodes observed and was limited
to patients treated with UFH/VKA. Hemorrhage
occurred at a higher rate among patients treated
with UFH/LMWH/VKA. LMWH/VKA treatment
was associated with lower rates of hemorrhage and
thrombus propagation.
Table 5 shows 30-day readmission rates for DVT
and PE admissions. Rates of 30-day readmission
were 26% and 24% in DVT and PE groups, respec-
tively. More than 72% of readmissions were due to
reasons other than DVT, PE, or hemorrhage.
In-hospital mortality (Table 4) was greater
among PE versus DVT admissions; only three
instances in the DVT population. For PE admis-
sions, the rate of in-hospital mortality was highest
in the LMWH/VKA group and lowest among
patients treated with UFH/VKA (2.7% vs. 1.6%).
Hospital Costs
Mean hospital costs by type of admission and treat-
ment are provided in Table 4. UFH/VKA treatment
was associated with lower anticoagulant and total
medication costs (Fig. 3). Treatment with LMWH/
VKA was associated with higher medication costs
but lower overall hospitalization costs (Fig. 3).
UFH/LMWH/VKA treatment was associated with
both higher drug and hospitalization costs (Fig. 3).
Validation Study
A total of 102 primary VTE admissions were iden-
tiﬁed. Data from charts conﬁrmed that all patients
were admitted with a primary diagnosis of VTE;
positive predictive value (PPV) of 100%. Sufﬁcient
information was available to calculate time to ther-
apeutic INR in 63 episodes. The mean time to
therapeutic INR in this group was 5.69 days
(±2.99 days). Time to reach a therapeutic INR was
a signiﬁcant predictor of LOS in the combined val-
idation sample of VTE admissions (chart review
sample). On average, each additional day required
to reach a therapeutic INR was associated with an
additional 0.72 (95% CI 0.41–1.04) hospital days.
Discussion
This analysis was undertaken to explore treatment
patterns and explore resource utilization and hospi-Ta
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tal costs associated with various treatment strate-
gies for VTE in an inpatient setting. The largest
number of admissions involved UFH/VKA treat-
ment. For the DVT patient sample, an unexpected
result was the relatively large number treated with
UFH/LMWH/VKA; this regimen was employed in
9% of DVT admissions. The relatively small size
(2.4%) of the LMWH monotherapy group was also
unexpected. A major difference between the DVT
and PE groups was the higher proportion of
patients treated with UFH/LMWH/VKA in the PE
group (15.7% vs. 9%). Among the three PE treat-
ment groups, the UFH/LMWH/VKA group com-
prised a greater proportion of severity class III and
IV patient episodes, indicating a higher proportion
of more severely ill individuals treated with this
regimen.
In general, the mean total costs for hospitaliza-
tion were comparable to previously reported ﬁgures
for the inpatient care of DVT and PE [9]. These hos-
pitalization costs paralleled LOS, with the LMWH/
VKA group having the lowest mean hospital costs
among the three treatment groups. The additional
total hospital costs in the UFH/LMWH/VKA group,
however, were greater than the corresponding LOS
results would suggest. In spite of the apparent
advantages of LMWH, UFH remains widely used.
UFH/VKA treatment was associated with the
lower mean anticoagulant and total medication
costs than treatment involving LMWH. Higher
total medication costs in the LMWH/VKA group,
however, were more than offset by lower overall
hospitalization costs, largely explained by a shorter
mean LOS in this group. The mean number of PTs
Figure 1 Distribution of  length of  stay for
DVT admissions by treatment groups. DVT,
deep venous thrombosis; LMWH, low-
molecular-weight heparin; LOS, length of
stay; UFH, unfractionated heparin; VKA, vita-
min K antagonist.
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Figure 2 Distribution of  length of  stay for
PE admissions by treatment group. LMWH,
low-molecular-weight heparin; LOS, length
of  stay; PE, pulmonary embolism; UFH,
unfractionated heparin; VKA, vitamin K
antagonist.
–5
0
5
10
15
20
25
0 5 10 15 20 25 30 35 40
Days to hospital discharge
Pe
rc
en
t (
%
) P
E 
ad
m
is
si
on
s
Utilization and Economic Outcomes for VTE 197
and aPTTs ordered was higher in regimens contain-
ing UFH than in the LMWH regimen. This was
expected because aPTTs are ordered as part of UFH
treatment therapy [5,6]. Analysis of adverse event
(thrombus propagation, hemorrhages, 30-day read-
mission) occurrence in both DVT and PE groups
resulted in slightly, but not signiﬁcantly, different
results.
In both the DVT and PE groups, those receiving
the UFH/VKA regimen experienced the lowest hos-
pital costs for anticoagulants and those receiving
the LMWH/VKA regimen experienced the highest.
These results were not wholly unexpected and
suggest that the LMWH component of the UFH/
LMWH/VKA regimen was given for a shorter
period of time than when it was given as a compo-
nent of the LMWH/VKA regimen.
Uncomplicated DVT is sometimes treated on an
outpatient basis [10–12]. Because our study popu-
lation includes only hospitalized patients, it may
consist of those with more severe disease than those
managed on an outpatient basis. Our results should
be seen in this context. Use of LMWH monotherapy
versus UFH/VKA may allow care for some patients
to be shifted from the inpatient to the outpatient
arena. Also, DVT and PE are increasingly being
seen as a single disease entity, with evidence that a
high percentage of patients with DVT alone have
asymptomatic PEs that can often be detected given
sufﬁcient diagnostic perseverance [13]. Further, to
the  extent  that  the  availability  of  LMWH  shifts
care of some patients entirely from the hospital to
the outpatient clinic or ofﬁce, the advantages of
LMWH over UFH would be enhanced. Such a shift
would bias inpatient comparisons in favor of UFH
to the extent that less seriously ill patients treated
with LMWH are treated as outpatients.
These results should also be seen in the context
of evolving practices with regard to anticoagulant
management, changes that have occurred while
pressures to reduce hospital utilization have
increased. Fourteen-day courses of intravenous
heparin followed by a transition to oral VKAs have
evolved to shorter periods on heparin alone, and
then to the current common practice of simultane-
ous initiation of heparin and VKAs [14,15]. The
latter practice introduces a management challenge
during the period when both heparin and VKA are
producing anticoagulation, a window during which
bleeding risk may be particularly high [14,15], and
possibly resulting in an extended LOS for some
patients.
PE admissions outnumbered DVT admissions
(four vs. one). Nevertheless, estimates based onTa
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National Hospital Discharge Survey (NHDS) data
suggest that there were nearly 150,000 hospitaliza-
tions for PE, versus approximately 400,000 for
DVT in the United States in 1999 [16]. The differ-
ence in the proportion of PE/DVT admissions
reported here versus in this NHDS-based study is
likely due to differences in criteria used to identify
VTE patients—we employed DRGs and additional
criteria in an attempt to identify hospitalizations
with VTE as the primary reason for admission.
Moreover, the authors of the NHDS-based study
used a variety of ICD-9 codes which may have
included hospitalizations in which VTE occurred
after admission for another reason. In addition, our
ﬁndings may reﬂect use of a speciﬁc, but not neces-
sarily sensitive, method for identifying DVT adm-
issions (i.e., many DVT admissions may not result
in a DRG speciﬁc to DVT being assigned). Also of
note are the more favorable reimbursement rates for
PE versus DVT episodes: the Medstat 2001 average
reimbursement was $10,920 for DRG code 78 (PE)
and $5450 for DRG code 128 (DVT). The large
number of VQ scans performed in the PE group
(0.87–1.25 scans per admission) across treatment
categories as compared with the DVT group (0.02–
0.56) is consistent with the hypothesis that such
scans often provide enough evidence to justify a PE,
versus a DVT DRG code.
This analysis has several limitations. Six treat-
ment strategies were identiﬁed from the analysis,
but three of these strategies could not be evaluated
because  of  small  sample  sizes;  in  particular,
the LMWH monotherapy group was too small to
include in the analysis. Another limitation was that
admitting diagnosis was not available. This neces-
sitated the development of an algorithm to select
admissions for DVT and PE, as opposed to admis-
sions in which these conditions developed after
admission for another reason. Available data did
not allow for separation of admissions with an
admitting diagnosis of PE and those with an admit-
ting diagnosis of DVT and subsequent occurrence
of a PE.
Additional limitations include potential differ-
ences among patients treated with different regi-
mens that may confound comparisons. Although
adjustment for demographic factors or disease
severity was judged to be of little utility given the
high degree of similarity of the groups being
compared, other factors for which we were unable
to adjust could confound these ﬁndings (e.g., con-
founding by indication). For example, patients
treated with LMWH/VKA might have had a more
favorable clinical prognosis that would have
resulted in shorter LOS regardless of the treatment
employed. Randomized clinical trials would be
Table 5 Frequency of  30-day readmissions by type
Reason for readmission
DVT
% of  readmissions
(n = 95)
PE 
% of  readmissions
(n = 521)
By primary diagnoses
VTE-related readmission 26.3 23.6
Hemorrhage/bleed-related readmission 1.1 2.7
Other readmission 72.6 73.7
Most prevalent reasons for 30-day readmissions
(“Other” Category) with ICD-9
038.19—Other staphylococcus septicemia, unspeciﬁed 1.1 0.4
038.9—Unspeciﬁed septicemia 1.1 1.2
153.4—Malignant neoplasm of  cecum 1.1 —
154.1—Malignant neoplasm of  rectum 1.1 —
197.6—Secondary malignant neoplasm of  retroperitoneum and peritoneum 2.1 0.4
197.7—Secondary malignant neoplasm of  liver 3.2 —
276.5—Volume depletion 3.2 1.2
427.31—Atrial ﬁbrillation — 1.3
428—Congestive heart failure 1.1 5.0
440.29—Other atherosclerosis of  native arteries of  extremities 2.1 —
486—Pneumonia, organism unspeciﬁed 3.2 2.5
491.21—Obstructive chronic bronchitis with acute exacerbation — 2.3
599—Urinary tract infection, site not speciﬁed — 1.2
682.6—Other cellulitis and abscess, leg, except foot 3.2 —
780.2—Syncope and collapse 1.1 1.0
786.59—Chest pain, other 3.2 1.5
V57.1—Care involving use of  rehabilitation procedures, other physical therapy — 1.2
V57.89—Care involving use of  rehabilitation procedures, other speciﬁed
rehabilitation procedure
4.2 3.8
V58.1—Chemotherapy — 1.7
DVT, deep venous thrombosis; PE, pulmonary embolism.
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needed to fully address this issue. Such potential for
confounding should be taken into consideration
when interpreting these ﬁndings.
The potential for more cost-effective manage-
ment of patients requiring anticoagulation is wor-
thy of further exploration. More widespread use of
LMWH might allow for shorter hospital stays and
more outpatient management, while reducing risks
that arise from simultaneous use of multiple antico-
agulants. Development of other oral agents with
improved properties such as a rapid onset of action
and a wider therapeutic window might also facili-
tate outpatient management [17,18].
Source of ﬁnancial support: This study was supported by
an unrestricted research grant from AstraZeneca Pharma-
ceuticals LP, Wilmington, DE.
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